Patent Grant
10696694
The present invention relates to the technical fields of crystallization and crystallography. More specifically, the invention concerns new lanthanide complexes which can be used as phasing agents for the determination of the crystal structure of biological macromolecules, but also as an aid for their crystallization. The invention is also intended to be used in these fields and the crystallization and determination of structural data which implement them.
The resounding success of the full determination of the human genome in 2000 paved the way for an even broader area of research: structural genomics, which involves determining the structure of proteins to understand the relationships between their structure and function. Due to the number and variety of proteins available, this is a huge project whose scope in terms of scientific and medical benefits is invaluable. Today, the two tools for this structural resolution are crystallography and nuclear magnetic resonance (NMR). These are two complementary techniques with advantages and limitations: (i) NMR allows protein solution analysis but requires isotopic enrichment; (ii) crystallography allows faster determination of structures but remains dependent on the preparation of good quality crystals. Currently, the research effort is focused on the development of very large instruments to the detriment of the search for new methodologies.
In this area, several successive difficulties have to be overcome. The first difficulty is in the field of biology and concerns the preparation and purification of proteins of interest and only 18% of cloned proteins pass this stage. The second difficulty concerns the crystallization stage, since again only 20% of the purified proteins can be crystallized and only half of these crystals will allow the structure to be determined by X-ray diffraction. On balance, only 1.8% of cloned proteins are structurally characterized and this, at the cost of considerable investment in terms of time and human and financial resources.
A crystal of a protein, or more generally a biological macromolecule, consists of a regular and periodic stacking of the molecules that make up the protein. Stacking is maintained by contacts within the crystal (hydrogen bonds, salt bridges, hydrophobic contacts). Obtaining a crystal from a biological macromolecule is a key step in determining its structure by X-ray crystallography.
It should be noted that the crystallization processes of biological macromolecules are still far from being understood and that current approaches are based on an empirical trial and error approach.
One of the important notions to consider in crystallogenesis is the concept of solubility. In solution, a macromolecule is surrounded by a solvent-based layer that has a repellent and insulating effect and avoids self aggregation and precipitation. Crystallization goes against this effect, since it involves moving away from the solubility conditions of the biological macromolecule by adding a precipitating agent, also called a crystallizing agent. For the purposes of this description, “precipitating agent” and “crystallizing agent” are used interchangeably. crystallizsing/precipitant means a molecule or mixture of molecules which, under certain conditions, help to form a crystal of biological macromolecules.
The general principle of crystallization is based on the diagram presented in
The two main steps that occur in the crystallization process are: nucleation and crystal growth. The crystallizing agent induces a change in solubility and therefore in the position on the diagram as a function of time. There are different crystallization methods using a crystallizing agent. The crystallizing agent induces a change in solubility and therefore in the position on the diagram as a function of time. There are different crystallization methods using a crystallizing agent.
The aim during crystallization is to play on the concentrations of biological macromolecule and crystallizing agent in order to reach the nucleation zone represented on the diagram in
These agents have the effect:
In all these cases, crystalline growth occurs in contact with these “impurities”. The most successful work in this area is that of Naomi E. Chayen's team, which proposes the use of mesoporous materials, capable of inducing nucleation in pores after a concentration/aggregation stage within the pores (WO 02/088435). The same group also describes the use of MIP “molecular imprinted polymers” based on the same principle. These are polymers previously printed by the protein to be crystallized and which therefore contain traces of it. Added to the crystallization drop, a form interaction can occur that favors nucleation (Saridakis, PNAS, 2001, 108,11081). All these crystallization aid agents are solids forming a heterogeneous phase in the crystallization medium, each of which must therefore be added manually to the crystallization drop, which is incompatible with the use of robotic screening platforms, except for MIP.
Moreover, due to the gigantic size of biological macromolecules, such as proteins, the determination of their structure by X-ray diffraction involves solving the problem of crystallographic phases. This implies having a native crystal (pure protein) and/or a derivative crystal containing a heavy atom easily identifiable and allowing to remove the problem of phases, we speak of phasing agent. The most classical method, based on muitiwavelength anomalous diffraction (MAD) is based on the replacement of the sulphur of the amino acids methionines of the protein by a selenium atom. Used since the 1990s, this method has revolutionized macromolecular crystallography, but it involves the synthesis, purification, crystallization and resolution of the structure of analogous selenium proteins. This is a very time-consuming method. Other exogenous phasing agents can be used and are marketed, such as bromine, heavy metals (Pt, Au, Hg). In this context, R. Kahn showed in the early 2000s that lanthanides, which have some of the most intense anomalous effects, can be included as complexes in protein crystals, which allows the structure of the macromolecule to be resolved quickly if lanthanide is fixed (E. Girard, M. Stelter, P. L. Anelli, J. Vicat, R. Kahn, Acta. Cristallogr. D, 2003, D59, 118; E. Girard, P. L. Anelli, J. Vicat, R. Kahn, Acta. Cristallogr. D, 2003, 059, 1877). To date, five lanthanide complexes are marketed as phasant agents by NatX-ray.
It exists in the literature some phasing luminescent agents, such as functional derivatives of DPA3 (FR 2 991 322 et ACIE 2008) or complexes of lanthanide directly grafted to the structure of proteins (X. C. Su, H. B. Liang, K. V. Loscha and G. Otting, J. Am. Chem. Soc., 2009, 131, 10352-10353).
Of all these derivatives, the tri-anionic complexes [(DPA)3Ln]3− seemed very promising because specific interactions with cationic amino acids and, in particular, arginine, were highlighted by some of the inventors of this patent application (E. Dumont, G. Pompidor, A. D'Aléo, J. Vicat, L. Toupet, R. Kahn, E. Girard, O. Maury, N. Giraud, Phys Chem Chem Phys 2013, 15, 18235-18242), and confirmed by NMR measurements (X. C. Su, H. B. Liang, K. V. Loscha, G. Otting, J. Am. Chem. Soc., 2009, 131, 10352-10353). Unfortunately, this compound has been shown to be unstable in a large number of commercial crystallization kits; (i) the presence of transition metals (Zn (II), Cu (II), Fe (II)) induces the destructuring of the complex, (ii) the presence of divalent alkaline earth salts (Ba (II), Ca (II), Mg (II)) induces immediate self-crystallization of the complex giving rise to false positives detection (crystals of complexes and not of crystals derived from proteins) (Doctoral thesis of R. Talon supported defended in Grenoble on Jun. 6, 2012).
Other solutions have proposed to introduce lanthanides into protein crystals to obtain a phasant effect. Nagem et al. (Nagem, R. A., Dauter, Z. & Polikarpov I, Acta Crystallogr. D, 2001, D57, 996-1002) proposed the use of lanthanide salts and the rapid soaking method (Dauter Z., Dauter, M. & Rajashankar, K. R. Acta Crystallogr. D, 2000, D56, 232-237). This method, originally developed for the haiogenide salts (NaCl, NaI, NaBr) consists of soaking the crystals in a highly concentrated salt solution (>1 mol L−1) for a time of less than one minute. In the case of lanthanide salt, this method led to rapid crystal degradation. Purdy et al (Purdy M. D., Ge P., Chen 1, Selvin P. R., & Wiener, M. C. Acta Crystallogr. D, 2002, D58,1111-1117) proposed to use a covalent bond linking lanthanide complexes (where the ligand provides complete coordination of lanthanide) to the protein. The binding consists of a disulfide bridge formed between free cysteines of the protein and a thiol reactive function carried by the complex. Finally, Silvaggi et al. (Silvaggi, N. R., Martin, L. 1, Schwalbe, H., Imperiali, B., Allen, K. N. 1, Am. Chem. Soc, 2007 129,7114-7120) proposed the use of a “tag” fixing one or two lanthanides (LBT for Lanthanide-Binding Tag). LBT is based on a peptide sequence derived from calcium loops that can be introduced into proteins by conventional molecular biology techniques (Allen, K. N. Imperiali B., Current Opinion in Chemical Biology, 2010, 14, 247-254).
There is therefore a need for new phasing agents that do not require modification of the structure of biological macromolecules, the structure of which is to be determined. In addition, the invention proposes to provide phasing agents which are sufficiently stable in most conditions of crystallization of biological macromolecules and which also make it possible to broaden increase the possibilities of obtaining crystals allowing to obtain structural informations on the biological macromolecules of interest. In this context, the invention concerns cationic complexes consisting of a lanthanide Ln3+ and a ligand of formula (I):
The ligands of formula (I) comprise at least 7 coordination sites for a lanthanide ion Ln3+, or more, depending on the structures of X and Y. These coordination sites are located on the two nitrogen atoms represented on formula (I), on the two pyridines of the R1, on the two R7 groups, at least one coordination site is located on X and/or Y.
The complexes according to the invention, as well as the lanthanide complexes formed with ligands of the formulae (I.1) to (I.5), are cationic and have a positive charge greater than or equal to 1. They comprise a macrocyclic ligand incorporating several aromatic groups forming an open coordination sphere for the lanthanide ion. These aromatic groups, when the Ln3+ ion is Eu3+ or Tb3+, also act as antennas to sensitize the luminescence of lanthanide in the visible.
Furthermore, the complexes according to the invention, have the advantage of being water soluble and stable in most commercial crystallization media. In the context of the invention, these complexes have been shown to be of interest not only as a phasing agent when obtaining structural data, but also as an aid to crystallization. In particular, said complex is used as a nucleating agent and/or as a crystallizing agent in the crystallization of a biological macromolecule. Such applications had never been described or considered for lanthanide complexes formed with ligands of the formulae (I.1) to (I.5) already described in the literature (M. Mato-Iglesias et al., Inorg. Chem. 2008, 47, 7840-7851; Z. Palinkas et al., Inorg. Chem. 2009, 48, 8878-8889; A. Roca-Sabio et al., Dalton Trans, 2011, 40, 384-392 and M. Regueiro-Figueroa et al., Inorg. Chem. 2015, 54, 4940-4952 for ligand complexes (I.1) to (I.3) and A. Rodrigues-Rodrigues et al., Inorg. Chem. 2012, 51, 2509-2521, for ligand complexes (I.4) and (I.5)). Indeed, these complexes were prepared for fundamental studies of coordination chemistry of lanthanides (study of the stability of complexes formed with different lanthanides) and in the case of Gd, only applications as an MRI contrast agent were considered.
In an advantageous way, the complexes according to the invention, as well as their salts with anion, solvates and hydrates, are formed with a ligand corresponding to one of the following formulae:
with R1, R2, n and R4 as defined for formula (I).
As an example of salts, complexes according to the invention or complexes formed with one of the ligands (I.1) to (I.5) which are applied in the context of the invention, one can cite salts of a cationic complex with an anion (or several anions, depending on the charge of the complex) chosen from: Cl−, Br−, I−, OH−, NO3−, triflate, PF6−, SbF6−, B(Ph)4−, BF4−, sulphates, sulphonates, carbonates, phosphates, phosphonates and carboxylates. Sulphates and sulphonates may correspond to SO42−, HSO3− or R′SO3−, carbonates to CO32−,HCO2− or R′CO2−, phosphates and phosphonates to R′OPO32− and R′PO32− and carboxylates to R′CO2−, with R′ which may be, in particular, an alkyl or aryl group, in particular an alkyl group containing 1 to 4 carbon atoms or a phenyl group. In the form of salts, the complexes, depending on the invention, may also be in the form of hydrate or solvates, i.e. with at least one water or solvent molecule in the lanthanide coordination sphere. Preferably, the complexes according to the invention, as well as their salts with anion, solvates and hydrates, are formed with a ligand corresponding to the formula (IA):
wherein n=1 and R2=H, and R1 is as defined for the compounds of formula (I).
In an advantageous way, in the ligands of formula (I), (IA) to (IF), R1 represents:
with:
In the context of the invention, when a substituent represents a picolinyl group, it represents:
Preferably, the complexes according to the invention are chosen among the complexes of formula:
as well as their salts with anion, in particular their hydrochloride salt, solvates and hydrates. In an advantageous way, the complexes according to the invention or the complexes formed with one of the ligands (I.1) to (I.5) which find application in the context of the invention, as well as their salts with an anion, in particular their salt. hydrochloride, their solvates and hydrates, are formed with a lanthanide ion Ln3+, Ln being Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb or Lu, with Eu, Tb, Yb and Lu which are preferred.
The invention is also intended to use a complex depending on the invention, or a cationic complex consisting of a lanthanide ion Ln3+ and a ligand of the formulae (I.1) to (I.5) as previously defined, or a salt thereof with an anion, solvates or hydrates, as an aid to the crystallization of a biological macromolecule. In particular, said complex is used as a nucleating agent and/or as a crystallizing agent in the is crystallization of a biological macromolecule. All lanthanide complexes according to the invention or formed with a ligand of formula (I.1) to (I.5), are of interest for their nucleating or crystallizing effect. However, only terbium or europium complexes will exhibit luminescence properties in the visible. Also, if in the complex, Ln=Eu or Tb, the complex can also be used as a luminescent agent for the detection of crystals. The invention is also intended to use a complex according to the invention, or a cationic complex consisting of a lanthanide ion Ln3+ and a ligand of formula (I.1) to (I.5) as previously defined, or a salt thereof with an anion, solvates or hydrates, as an aid in obtaining structural data of a biological macromolecule. In particular, said complex is used as a phasing agent in the structural determination by X-ray diffraction. Again, if in the complex, Ln=Eu or Tb, the complex can also be used as an aid for positioning the crystal in an X-ray beam.
In particular, in the context of the invention, “biological macromolecule” means in particular peptides (sequence of less than 100 amino acids), proteins (sequence of at least 100 amino acids) and nucleic acids, in particular DNA or RNA. Such biological macromolecules shall in particular have an average molecular weight of more than 1 kDa.
The invention also has as its object the crystals of a biological macromolecule comprising a complex according to the invention or a cationic complex formed of a lanthanide ion Ln3+ and a ligand of formula (I.1) to (I.5) as previously defined, or a salt thereof with an anion, solvate or hydrate, called derivative crystals.
The invention also has as its object a process for crystallizing a biological macromolecule, preferably selected from peptides, proteins and nucleic acids, in particular DNA or RNA, comprising the following steps:
The solution used may also include a precipitating agent, other than the complex, chosen in particular from among those used in commercial crystallizsation kits, in particular from those listed in the tables presented in Annexes 2A or 2B, such as, for example, salts such as ammonium salts, sulphates (especially ammonium sulphate), acetates, phosphates, citrates (especially sodium citrate), formiates, tartrates such as sodium or potassium tartrate, double tartrate, sodium and potassium, chlorides, iodides and fluorides, for example NaCl; polymers such as polyethylene glycols and Jeffamine T; ethanol, dioxane, methylpentanediol, glycerol, isopropanol, 2-methyl-2,4-pentanediol.
In the solution, the complex is advantageously present at a concentration of 1 to 100 mM, preferably at a concentration of 1 to 25 mM, and even more favorably at a concentration of 10 mM±10%.
In particular, crystals are obtained by vapor diffusion crystallization, by dialysis, in batch or in a process of crystallization in the cubic phase of lipids.
The crystallization process, depending on the invention, can be integrated into a screening process or an optimization of the crystallization conditions of a biological macromolecule. The crystallization process according to the invention can be automated.
The invention shall also have as its subject matter a method of analyzing or determining the structure of a biological macromolecule comprising the following steps:
The derivative crystal may be obtained by a crystallization process as described in the invention or by soaking a crystal from the biological macromolecule in a solution of a complex according to the invention or a cationic complex consisting of a lanthanide ion Ln3+ and a ligand of formula (I.1) to (I.5) as previously defined, as well as their salts with an anion, their solvates or hydrates. The derivative crystal may also be obtained by soaking a derivative crystal from the biological macromolecule obtained by a crystallization process as described in the invention, in a solution of a complex according to the invention or a cationic complex consisting of a lanthanide ion Ln3+ and a ligand of formula (I.1) to (I.5) as previously defined, or of a salt thereof with an anion, their solvates or hydrates.
In particular, the analysis of the crystalline structure of the biological macromolecule from said derived crystal corresponds to the determination of the structure of the biological macromolecule and is carried out by X-ray diffraction (RX). It is also possible that it corresponds to the obtaining of structural data by a high resolution method, such as X-ray diffraction (RX) or by a low resolution method by SAXS methods (Small-Angle X-ray Scattering) or MASC (Multiwavelength-Anomalous Solvent Contrast).
The following detailed description provides a better understanding of the invention.
The cationic complexes formed from a lanthanide ion Ln3+ and a ligand of formula (I), corresponding to complexes according to the invention or complexes formed with a ligand of formula (IA) to (IF) are cationic complexes, and in particular mono-cationic complexes. They are therefore capable of producing crystals derived from a biological macromolecule. Such derived crystals can be obtained by dipping or co-crystallization, as detailed below. The anomalous effect due to the presence of lanthanides in the derived crystals obtained leads to a phasing effect and facilitates the determination of the structure of the biological macromolecule concerned, in particular by X-ray diffraction. Complexes depending on the invention can therefore be used as an aid in determining or analyzing the crystalline structure of a biological macromolecule.
The cationic complexes formed from a lanthanide ion Ln3+ and a ligand of formula (I), corresponding to complexes according to the invention or complexes formed with a ligand of formula (IA) to (IF), as well as their salts, solvates and hydrates may also be used as an aid in the crystallization of biological macromolecules. Indeed, depending on their structure and the crystallization conditions used, the complexes according to the invention have at least one of the following properties:
In particular, the lanthanide complexes formed with ligands of formula (I) consisting of a lanthanide ion Ln3+ and a ligand of formula (I), corresponding to the complexes according to the invention or complexes formed with a ligand of formula (IA) to (IF), as well as their salts, solvates and hydrates, either increase the number of conditions under which the crystal formation of a macromolecule is possible, or to work under conditions lower in biological macromolecule and/or other precipitating agent conventionally used, either to improve the quality or the number of crystals thus favoring the obtaining of subsequent structural data, or to obtain several of these advantages.
The Europium and Terbium complexes also have the advantage of being luminescent under UV irradiation. Thus, their use allows an easy identification of the derived crystals during crystallization tests. This property can be used as a rapid detection method for crystallization platforms equipped with an automatic UV imaging device. In addition, this property can be used as an aid for centering in an X-ray beam during diffraction characterization, in particular.
Complexes depending on the invention may be prepared according to techniques adapted by the skilled person, techniques described in the examples or in application WO 2014/162105. The synthesis of complexes according to the invention is usually carried out in water. The complexes thus formed will therefore be more in the form of hydrate, but this complex can then be put in a different solvent, such as alcohol or DMSO, and give rise to a solvate or be dehydrated. In hydrated form, a complex according to the invention will contain up to 3 molecules of water per complex. On average, the number of water molecules per complex may, however, be different from an integer, e.g. equal to 0.5. For the applications envisaged in the context of the invention, lanthanide complexes depending on the invention may be used in hydrated form, or dehydrated, solvated or not, in powder form or in solution.
The quality and purity of a crystallizing agent are essential for the smooth implementation of the macromolecule crystallization when used as a crystallizing agent. Finally, lanthanide complexes according to the invention will be subjected to an appropriate purification step, in particular by steric exclusion chromatography.
The cationic complexes consisting of a lanthanide ion Ln3+ and a ligand of formula (I), corresponding to the complexes according to the invention or complexes formed with a ligand of formula (IA) to (IF), as well as their salts, solvates and hydrates, may be used as a crystallizing agent in any technique suitable for the crystallization of biological macromolecules.
For a detailed description of such techniques, reference can be made to the following reference works: <<Protein Crystallization, Second Edition (IUL Biotechnology Series)>> edited by Therese Bergfors or <<Crystallization of Nucleic Acids and Proteins: A Practical Approach>> edited by Arnaud Ducruix and Richard Giegé.
In particular, cationic complexes formed from a lanthanide ion Ln3+ and a ligand of formula (I), corresponding to complexes according to the invention or complexes formed with a ligand of formula (IA) to (IF), as well as their salts, solvates and hydrates, may be used as a crystallizing agent in a process for the crystallization of biological macromolecules by vapor diffusion, dialysis, batch or in a method of crystallization in cubic phase of lipids.
These different techniques will each be described briefly, the crystallizing agent being a lanthanide complex or a mixture of crystallizing agents containing at least one lanthanide complex with a ligand of formula (I) in the form of salts, solvates or hydrates:
In these three approaches, a solution of the crystallizing agent is placed in a well (light grey solution). The solution containing the biological macromolecule of interest is mixed with the crystallizing agent and deposited as a drop (either suspended, sitting or as a sandwich). The crystallization well is hermetically sealed with a glass plate or plastic film. At the start of crystallization, the concentration of the crystallizing agent in the drop is twice as low as in the well. Once the system is closed, a diffusion kinetics of the solvent from the drop (usually water) towards the well is set up. The volume of the drop will therefore decrease (loss of solvent i.e. of water) and the concentrations of biological macromolecule and crystallizing agent will thus increase, allowing, in favorable cases, to reach the nucleation phase. In this method, the concentration of crystallizing agent is extremely important. Indeed, an excess of crystallizing agent could lead to a diffusion kinetics of the solvent too fast and thus lead to the precipitation of the biological macromolecule. On the contrary, a too low concentration will not reach the nucleation zone. The concentration of the appropriate crystallizing agent will therefore be determined by routine tests carried out by the skilled worker. From the nucleation, crystalline growth will then decrease the concentration of soluble macromolecule until it reaches a stationary state.
The general principle is to slowly increase the concentration of the crystallizing agent. For this purpose, a solution containing the relevant biological macromolecule is placed in a dialysis container, e.g. capillary type or dialysis button closed by a semi-permeable membrane allowing the molecules of crystallizing agent (but not the macromolecule) to pass through. This container is then placed in a solution of crystallizing agent. An equilibrium between the solution containing the biological macromolecule of interest (which does not contain a crystallizing agent) and the external solution containing the crystallizing agent will be established. Thus, the concentration of the crystallizing agent in the dialysis container will increase and modify the solubility of the macromolecule. This technique has the advantage of being more precise than vapor diffusion with respect to maintaining pH and volume. However, the handling of crystals remains much more delicate.
The principle of this technique, shown schematically in
The techniques of steam diffusion crystallization, crystallization by means of dialysis or batch crystallization work on all types of proteins, whether water-soluble or membranous, then soluble in detergent, as well as on other biological macromolecules (DNA, RNA, protein complexes, protein-DNA or RNA complexes, etc.).
For the crystallization of membrane proteins, it is also possible to use a lanthanide complex as a crystallizing agent in a technique of cubic phase lipid crystallization. The cubic phase crystallization of lipids of membrane proteins is described in the following publications: Landau et al. Lipidic cubic phase: A novel concept for the crystallization of membrane proteins, PNAS Vol. 93 no. 25 14532-14535 (1996), Caffrey et al. Crystallizing membrane proteins using lipidic mesophases. Nat Protoc 4 (5) 706-31 (2009), Cherezov V., Lipidic cubic phase technologies for membrane protein structural studies. Curr. Opin Struct Biol Vol 21 559-566 (2011).
Lanthanide complexes formed from a lanthanide ion Ln3+ and a ligand of formula (I), corresponding to complexes according to the invention or complexes formed with a ligand of formula (IA) to (IF), as well as their salts, solvates and hydrates are compatible with all crystallization methods which have just been detailed.
In particular, a solution containing a concentration of 1 to 100 mM, preferably 1 to 25 mM of a lanthanide complex formed from a lanthanide ion Ln3+ and a ligand of formula (I), corresponding to complexes according to the invention or complexes formed with a ligand of formula (IA) to (IF), in the form of a salt with an anion, optionally in the form of a solvate or hydrate and even more preferably 10 mM±10% will be used.
In crystallizations, in particular, in the vapor phase or batch, a solution of the biological macromolecule to be crystallized and a lanthanide complex consisting of a lanthanide ion Ln3+ and a ligand of formula (I), corresponding to the complexes according to the invention or complexes formed with a ligand of formula (IA) to (IF), in the form of a salt with an anion, optionally in the form of a solvate or hydrate (which, for simplification, will be referred to in the remainder of the description as a lanthanide complex), shall be prepared, preferably with a concentration of 1 to 100 mM, preferably 1 to 25 mM, and even more preferably at 10 mM±10%, as a lanthanide complex. The lanthanide complex formed from a lanthanide ion Ln3+ and a ligand of formula (I), corresponding to the complexes according to the invention or complexes formed with a ligand of formula (IA) to (IF), in the form of a salt with an anion, optionally in the form of a solvate or hydrate, can be directly solubilized by the solution containing the biological macromolecular to achieve a final complex concentration of 1 to 100 mM, preferably 1 to 25 mM, and preferably 10 mM±10% which corresponds to the concentration at which the nucleating effect is predominant. The lanthanide complex can also be introduced from a solution at a preferential concentration of 10 to 30 mM during the production of a crystallization drop: a volume of the macromolecular solution, an identical volume of the lanthanide complex solution and an identical volume of the well solution used for crystallization are then added successively.
In these crystallization techniques, the lanthanide complex and the biological macromolecule to be crystallized will generally be solved in water or in a buffered aqueous solution (see examples in the description of the crystallization kits in Annexes 2A and 2B), e.g. in an acetate, cacodylate, citrate, Bis tris propane, TRIS, HEPES, phosphate buffer solution. Solutions containing a biological macromolecule are usually buffered. If a solution of the lanthanide complex is formed, it will not necessarily be buffered. The solution containing the complex, the solution containing the biological macromolecule and/or the solution containing the biological macromolecule and the complex, depending on the crystallization technique used, will preferably have a pH in the range of 3 to 9.
Additives such as additives already known to act as precipitating/crystallizing agents or additives which initially facilitate the dissolution of the biological macromolecule to be crystallized may be added. Examples of these are those listed in the tables in Annex 2A or 2B, such as salts such as ammonium salts, sulphates (especially ammonium sulphate), acetates, phosphates, citrates (especially sodium citrate), formiates, tartrates such as sodium or potassium tartrate, double sodium and potassium tartrate, chlorides, iodine, and fluorides, e.g. Nacl; polymers such as polyethylene glycols and Jeffamine T; ethanol, dioxane, methylpentanediol, glycerol, isopropanol, 2-methyl-2,4-pentanediol. In particular, lanthanide complex can be used in any crystallization solution already on the market.
The concentration of macromolecule in the solution will theoretically be close to its solubility limit in the said solution, but may be more diluted, depending on the solution used.
Lanthanide complexes consisting of a lanthanide ion Ln3+ and a ligand of formula (I), corresponding to the complexes according to the invention or complexes formed with a ligand of formula (IA) to (IF), in the form of a salt with an anion, optionally in the form of a solvate or hydrate, may also be used to obtain derivative crystals from biological macromolecules, i.e. crystals containing said lanthanide complex. In particular, said lanthanide complex will be fixed on a specific position of the biological macromolecule to be studied, allowing the determination of the structure of said studied biological macromolecule.
The determination of the phases can be carried out with derived crystals obtained in a solution containing 1 to 100 mM of complex, preferably 10 to 100 mM, and in an even more preferable way from 100 mM±10% to the said lanthanide complex. However, in order to improve the quality of phasing, a soaking in a solution of a lanthanide complex, in particular, with a high concentration of complex, can also be carried out. This allows to increase the occupancy rate of the sites occupied by the complex.
Co-crystallization therefore involves adding the lanthanide complex during the crystallization process. Thus, during crystallization, the lanthanide complex can be inserted into specific crystalline sites leading to the production of derivative crystals.
In addition, to obtain a derivative crystal or increase the occupancy by a lanthanide complex of sites in the derivative crystal, a soaking of a biological macromolecule crystal in a lanthanide complex solution can be performed. It is possible to carry out a rapid soaking or long time soaking.
Rapid soaking consists of taking a crystal from a biological macromolecule of interest and soaking it briefly (notably from 45 seconds to 2 minutes) in a solution of the lanthanide complex. The solution in which the crystal is hardened has a high concentration of lanthanide complex, typically 50 to 500 mM, preferably 100 mM±10%.
In particular, a rapid soaking during the freezing phase of one or more crystals can be achieved. A rapid soaking during a freezing phase typically takes place in three steps: crystals are taken from their original drop and soaked in a soaking drop, corresponding to a solution equivalent to the original solution used for the formation of the said crystal(s) to which is added a concentration of 50 to 500 mM, preferably 100 mM±10% of lanthanide complex, and a cryoprotectant agent. After 45 seconds to 2 minutes, the crystal is soaked in a cryoprotective solution without lanthanide complexes to remove its excess. Finally, the crystal is immersed in liquid nitrogen and stored at low temperature, for example at 100K.
This soaking method is very efficient and allows to increase the occupancy rates and improve the quality of the phasing. For example, in the case of PhP1 protein, a 45-second soaking in a 100 mM complex solution increased the occupancy rate of the complex by 3. Rapid soaking prevents crystal from deteriorating and preserves its diffraction properties.
Long time soaking consists of taking a crystal from a biological macromolecule of interest and soaking it for a prolonged period of time (notably from 10 minutes to 24 hours) in a solution of the lanthanide complex. Advantageously, the solution in which the crystal is soaked has a high concentration of lanthanide complex, typically a concentration of 50 to 500 mM, preferably 100 mM±10%.
With the exception of duration, long time soaking can take place according to the same protocol as described for rapid soaking, especially during a freezing phase. However, the soaking drop is placed in equilibrium with a well containing the original solution used for the formation of the said crystal(s) in order to avoid dehydration of the drop.
Regardless of the type of soaking, it is possible to soak both crystals obtained by co-crystallization in the presence of a lanthanide complex and crystals obtained in the absence of such a complex (named native crystals in the context of this patent application). Soaking does not lead to any destruction or modification of the biological macromolecule. Lanthanide complexes allow to form derivative crystals from a biological macromolecule to obtain structural data for said biological macromolecule. In particular, structural data will be obtained from a derivative crystal from a biological macromolecule containing a lanthanide complex that acts as a phasing agent. These structural data can be obtained using a high-resolution method, such as the diffraction of X-rays (RX) or by a low resolution method, such as SAXS and MASC. Lanthanide complexes may be used as a phasing agent in X-ray diffraction (crystallization and structural analysis) or X-ray scattering, or as a contrast agent in SAXS or MASC, in electronic microscopy.
The use of lanthanide complexes consisting of a lanthanide ion Ln3+ and a ligand of formula (I) corresponding to the complexes according to the invention or complexes formed with a ligand of formula (IA) to (IF), in the form of a salt with an anion, optionally in the form of a solvate or hydrate, in particular as a phasing agent, has the advantage of not requiring a modification of the biological macromolecule by genetic engineering, as in the case of obtaining selenium proteins. There is no covalent binding between the lanthanide complex and the biological macromolecule of interest.
The following examples, with reference to the attached figures, illustrate the invention but are not specific.
Part I: Synthesis and Characterization of Complexes
The following abbreviations are used:
Me=methyl; Moz=methoxyybenzyloxycarbonyl; Boc=tert-butoxycarbonyl; Ms=mesyl; Et=ethyl; TA=ambient temperatura; Ac=acetyl; DCM=dichloromethane; TACN=triazacyclononane; DMF=dimethylformamide; TFA=trifluoroacetic acid; ACN=acetonitrile; CCM=thin layer chromatography
Starting Materials and Characterization
All starting materials, solvents and salts of lanthanide were purchased from Sigma-Aldrich®, Acros Organics® and TCI® with purities greater than 98% for organic compounds and greater than 99.99% for lanthanide salts. These products were used directly without additional purification.
Chromatographs were carried out on neutral alumina activity III obtained by hydration of Acros Organics® alumina activity I (60Â) and on silica gel Acros Organics® (60 Å). The formed complexes have all been purified by Sephadex® steric exclusion column LH20.
The NMR spectra (1H, 13C) were recorded on two Bruker® Advance devices operating at 500.10 MHz and 125.75 MHz for 1H and 13C respectively, and at 300 MHz for 1H for the second. Chemical displacements are partially reported per million (ppm) relative to the tetramethylsilane signature (1H, 13C), with residual solvent peaks being used as internal reference.
The exact mass measurements were carried out at the Joint Centre for Mass Spectrometry (Villeurbanne, France).
A) Preparation of a First Batch of Triazacyclononane-Based Ligands/Complexes (TACH)
Compound 6 was prepared according to the procedure previously described in patent application WO2013/011236A1.
A1) Preparation of Compound 1
To a suspension of 20 g dipicolinic acid (0.12 mol, 1 eq.) in 120 mL methanol, 1 mL concentrated sulphuric acid is added. The mixture is carried in reflux for 24 hours. After cooling, the crystallized product is filtered and rinsed with cold methanol to give, after drying, 18 g of white crystalline powder of compound 1. (R=78%). 1H-NMR (300 MHz, CDCl3) δ (ppm)=8.26 (d, J=8 Hz, 2H), 7.99 (t, J=8 Hz, 1H), 3.98 (s, 6H).
A2) Preparation of Compound 2
18 g compound 1 (92 mmol, 1 eq.) are dissolved in 450 ml methanol and cooled to 0° C. 3.8 g NaBH4 (101.2 mmol, 1.1 eq.) are then added. The mixture is then stirred 30 min at 0° C. and 30 min further, leaving the temperature slowly rising to RT. The reaction is stopped by adding 50 mL HCl (1M in H2O), then the organic phase is extracted with 100 mL dichloromethane. After washing the organic phase with brine (up to pH=7), drying with Na2SO4 and evaporation, the obtained product is purified by chromatography on silica gel (eluent: DCM/AcOEt 9/1 v/v up to pure AcOEt). We obtain 6 g of a white solid of compound 2 (R=40%). 1H-NMR (300 MHz, CDCl3) δ (ppm)=8.01 (d, J=8 Hz, 1H), 7.84 (t, J=8 Hz, 1H), 7.53 (d, J=8 Hz, 1H), 4.85 (d, J=3 Hz, 2H), 3.98 (s, 3H), 3.69 (bs, 1H).
A3) Preparation of Compound 3
3 mL of Et3N (22 mmol, 3.2 eq.) is added to a solution of 1.2 g of alcohol 2 in 50 mL of dichloromethane at 0° C. and rapidly followed by 0.79 mL of mesyl chloride (10.2 mmol, I, 5 eq.). The mixture is then allowed to return at room temperature before heating for 1 hour at 50° C. Then 40 mL of water is added and the dichloromethane mixture (3×20 mL) is extracted. The obtained oily residue, after drying and evaporation of the organic phases, is finally purified on silica gel (eluent: CH2Cl2) to obtain a colorless oil of compound 3 which crystallizes in the freezer.
1H NMR (500 MHz, CDCl3) δ 8.12 (d, J=7.7 Hz, 1H), 7.93 (t, J=7.8 Hz, 1H, H10), 7.70 (d, J=7.8 Hz, 1H), 5.44 (s, 2H, H7), 4.01 (s, 3H, OMe), 3.15 (s, 3H, OMs).
13C NMR (126 MHz, CDCl3) δ 165.33 (C13), 154.59 (s), 147.92 (s), 138.45 (C10), 125.41 (s), 125.13 (s), 71.11 (C7), 53.23 (OMe), 38.24 (OMs).
A4) Preparation of compound 6
Compound 6 is prepared by the method described above, (a) WO2013011236A1; b) 1.S. J. Butler, B. K. McMahon, R. Pal, D. Parker and J. W. Walton, Chem. Eur. J., 2013, 19, 9511-9517.)
A5) Preparation of compound 7
360 mg of compound 6 (1.19 mmol) and 760 mg of sodium carbonate (7.15 mmol, 6 eq.) are dried under reduced pressure in a schlenk before adding 100 mL of acetonitrile. Under argon, 710 mg of compound 3 (2.74 mmol, 23 eq.) are added to the suspension before heating for 12 h at 70° C. After return to room temperature, the mixture is filtered on sintered (porosity 4) and concentrated under reduced pressure. The product is purified by alumina chromatography (activity III, eluent DCM then DCM/MeOH 96/4 v/v) to finally obtain a yellow oil of compound 7 (532 mg, Yield: 80%).
1H NMR (500 MHz, CDCl3) δ 7.99 (dd, J=6 Hz, 2H, H11), 7.86-7.65 (m, 4H, H9), 3.98 (s, 10H, H7+OMe), 3.39 (d, J=30 Hz, 4H, H4H5), 3.11 (s, 2H, H3H6), 2.95 (s, 2H, H3′H6′), 2.66 (d, J=31 Hz, 4H, H1H2), 1.44 (s, 9H, boc).
13C NMR (126 MHz, CDCl3) δ 166.01, 166.09 (C13), 161.43, 161.60 (C8), 155.88(CO(boc)) 147.45 (C12), 137.42 (d,C10), (s), 126.19, 126.46 (C9), 123.70 (C11), 79.48 (C(boc)), 63.70 (d, C7), 57.21 (C1C2), 55.37 (s), 55.11 (s), 54.67 (s), 53.04 (OMe), 50.54, 49.95 (C4C5), 28.72 (CH3(boc)).
A6) Preparation of Compound 8
In 100 mL dichloromethane, 5 mL trifluoroacetic acid is added to a 427 mg solution of compound 7. After 5 hours of agitation at room temperature, the mixture is evaporated by removing the TFA by drive with several toluene additions. The resulting residue is purified by alumina chromatography (activity III, eluent DCM/MeOH (gradient 1% to 7%)). The viscous yellowish solid obtained from compound 8 is stored under argon in the freezer (mass: 315 mg, yield: 90%).
1H NMR (500 MHz, CDCl3) δ 7.96 (dd, J=7.7, 0.5 Hz, 2H, H11), 7.71 (t, J=8 Hz, 2H, H10), 7.42 (dd, J=7.9, 0.5 Hz, 2H), 3.98 (d, 10H, H7+OMe), 3.40 (t, J=5 Hz, 4H, H4H5), 3.03 (t, J=5 Hz, 4H, H3H6), 2.71 (s, 4H, H1H2).
13C NMR (126 MHz, CDCl3) δ 65.37 (C13), 159.43 (C8), 147.59 (C12), 137.87 (C10), 126.10 (C9), 124.02 (C11), 60.95 (C7), 54.60 (C1C2), 53.31 (OMe), 51.66 (C3C6), 46.52 (C4C5).
NB: the synthesis of this compound has been previously described in the following reference: A. Nonat, C. Gateau, P. H. Fries, M. Mazzanti, Chem. Eur. J., 2006, 12, 7133.
A7) Preparation of Compound 9
Ligand 9 is generated in situ by saponification of diester 8 in the presence of sodium carbonate Na2CO3 (2 eq.) in a MeOH/H20 mixture (1/1, v/v) stirred for 3 hours at 50° C.
1H NMR (500 MHz, D2O) δ 7.77 (d, J=7.1 Hz, 2H, H9), 7.69 (t, J=7.7 Hz, 2H, H10), 7.29 (d, J=7.2 Hz, 2H, H11), 3.86 (s, 4H, H7), 3.08 (t, J=5.9 Hz, 4H, H4H5), 2.91 (t, J=5.9 Hz, 4H, H3H6), 2.65 (s, 4H, H1H2).
13C NMR (126 MHz, D2O) δ 173.22 (C13), 158.44 (C8), 153.01 (C12), 138.23 (C10), 125.17 (C11), 122.40 (C9), 60.27 (C7), 50.53 (C1,C2), 47.12 (C3,C6), 44.10 (C4,C5).
A8) Preparation of Compound 10
After reaction for 3 h at 50° C. of 110 mg diester 8 (0.26 mmol) with 83 mg Na2CO3 (0.78 mmol, 3.0 eq.) and neutralization by HCl (1M), the disappearance of the ester is verified by NMR. 96 mg terbium chloride (0.26 mmol, 1 eq.) are added to compound 9, formed in situ, before stirring the mixture for 12 hours at 50° C. Solubilized in a minimum of methanol, complex 10 is then separated from the various salts by centrifugation. The last traces of salts are removed by passing through a steric exclusion column (LH20, Sephadex®, eluent: water). MS (ESI-TOF) calculated M+: 556.1003; measured: 556.0990
A9) Preparation of Compound 11
An identical protocol to that/the one used for the preparation of Complex 10 is used with 170 mg diester 8 (0.4 mmol) and 219 mg EuCl3,6H20 (0.6 mmol, 1.5 eq.). MS (ESI-TOF) calculated M+: 550.0962; measured: 550.0957.
B) Preparation of a Second Series of Triazacyclononane-Based Ligands (TACN)
B1) Preparation of Compound 12
15 g of monohydric chelidamic acid (0.075 mol, I eq.) are dissolved in 120 mL of thionyl chloride under argon. The suspension is cooled to 0° C. and 3 mL DMF are added. The reaction mixture is then stirred for 12 hours with reflux. Volatiles are evaporated after several toluene additions to remove the last traces of SOCl2. The resulting yellowish solid is then dissolved in methanol and the mixture is refluxed for 12 hours to complete the reaction. After evaporation of the solvent, the residue is taken up by dichloromethane and washed successively with a saturated solution of NaHCO3, water and brine. The organic phase is then dried on Na2SO4, filtered and evaporated. Pure compound 12 is obtained by recrystallization in methanol to obtain 8.3 g of white crystalline powder. (R=44%).
1H-NMR (300 MHz, CDCl3) δ (ppm)=8.29 (s, 2H), 4.03 (s, 6H).
B2) Preparation of Compound 13
6 g of compound 12 (0.026 mol, I eq.) are dissolved in 250 mL of a DCM/methanol mixture (150/100, v/v) and the solution is cooled to 0° C. Then, 1.09 g of NaBH4 (0.029 mol, 1.1 eq.) are added in one step before stirring the mixture for 30 min at 0° C. and 30 min at RT. The reaction is stopped by the addition of 50 mL hydrochloric acid (1M) and 100 mL of water. The organic phase is then washed with water to a pH=7, then washed in brine, dried on Na2SO4 and evaporated. The reaction crude is then purified on silica gel (eluent: DCM/acOEt 1/1 v/v) to obtain after evaporation 1.5 g of a white powder of compound 13 (R=30%).
1H-NMR (300 MHz, CDCl3) δ (ppm)=8.00 (bd, 1H), 7.60 (bd, 1H), 4.85 (d, J=7 Hz, 2H), 3.99 (s, 3H) 3.48 (t, J=7 Hz, 1H).
B3) Preparation of Compound 14
1.5 g of compound 13 (7.4 mmol, 1 eq.) are dissolved in 200 mL dichloromethane and 3 mL triethylamine are added (22.2 mmol, 3 eq.). Then 0.87 mL of mesyl chloride is added (11.1 mmol, 1.5 eq.) slowly and a progressive yellow coloring of the mixture is observed. The reaction progress is followed by CCM and stopped after 30 min. 100 mL of a saturated solution of NaHCO4 are added and the organic phase is washed with water (up to pH=7) and brine. The organic solution is then dried on Na2S04 and evaporated to give 2 g of a yellow oil of compound 14 used without further purification (quantitative yield).
1H-NMR (300 MHz, CDCl3) δ (ppm)=8.1 (s, 1H), 7.68 (s, 1H), 5.40 (s, 2H), 4.01 (s, 3H), 3.17 (s, 3H).
B4) Preparation of Compound 15
200 mg of triazacyclononane mono-boc (0.7 mmol, I eq.) are suspended in 100 mL of dry acetonitrile with 420 mg of anhydrous sodium carbonate. 463 mg of compound 3.3 (1.75 mmol, 2.5 eq.) are then added. After cooling, the mixture is sintered to remove the carbonate before evaporation of the solvent. The residue is taken up in dichloromethane and purified by alumina column chromatography (activity III, eluent: dichloromethane and ethyl acetate). 250 mg of a yellow solid of compound 15 (R=63%).
1H-NMR (300 MHz, CDCl3) δ (ppm)=8.00 ppm (d, J=1 Hz, 1H), 7.99 (d, J=1 Hz, 1H), 7.89 (d, J=1 Hz, 1H), 7.72 (d, J=1 Hz, 1H), 3.99 (m, 10H), 3.39 (m, 4H), 3.03 (m, 4H), 2.67 (m, 4H), 1.48 (s, 9H). LC-MS: [M+H]+=596.2 m/z.
B5) Preparation of Compound 16
3 mL trifluoroacetic acid is added to a 110 mg solution of compound 15 in 60 mL of dichloromethane, The mixture is then stirred for 12 hours at room temperature. The solvent is then evaporated and the TFA is evaporated by several additions of a methanol/toluene mixture. The residue is then taken up by 50 mL of dichloromethane and washed with water to pH=7. The organic phase is then dried on Na2SO2 and evaporated to obtain 100 mg of white powder of compound 16. (R−95%).
1H-NMR (300 MHz, CDCl3) δ (ppm)=7.97 (d, J=1 Hz, 2H), 7.54 (d, 7=1 Hz, 2H), 4.04 (s, 6H), 4.03 (s, 4H), 3.35 (m, 4H), 3.00 (m, 4H), 2.76 (s, 4H).
13C-NMR (75 MHz, CDCl3) δ (ppm)=163.91, 160 (q, J=40 Hz), 147.58, 146.99, 126.49, 125.22, 60.37, 53.80, 53.56, 53.28, 45.39.
HR-MS: [M+H]+=496.1501 m/z, theor. for C22H28Cl2N4O4 is 496.1513 m/z.
B6) Preparation of Compound 17
100 mg of compound 16 (0.2 mmol, 1 eq.) are suspended in 30 mL of water and 32 mg of sodium hydroxide (0.81 mmol, 4 eq.) are added. The mixture is then stirred at 60° C. during one hour. The complete hydrolysis of the ester functions is confirmed by LC-MS. The solution is then cooled and its pH is adjusted to 5 with a progressive addition of a hydrochloric acid solution (1M). 5 mL of methanol is then added before introducing 42 mg of sodium carbonate to the solution. 91 mg of TbCl3, 6H2O are added before stirring the mixture at 50° C. for 12 hours. After return to ambient temperature, the insoluble salts are filtered on sintered glass before evaporation of the solvents to obtain 300 mg of raw product. The complex is purified by steric exclusion chromatography (Sephadex® LH20, eluent: water) to finally obtain 55 mg of a colorless crystalline product (yield=44%).
1H-NMR (300 MHz, D2O) δ (ppm)=121.1, 83.90, 69.15, 52.71, 46.23, 29.58, 26.06, −0.96, −11.39, −20.2, −33.57, −36.26, −44.20, −70.35, −91.19, −92.47, −120.84.
HR-MS: M+=624.0213 m/z, theor. for C20H21Cl2N5O4Tb 624.0219 m/z.
C) Preparation of a Third Series of Triazacyclononane-Based Ligands (TACN)
C1) Preparation of Compound 19
8.3 g of compound 12 (36 mmol, 1 eq.) are dissolved in 200 mL acetonitrile and 54 g sodium iodide are added (0.36 me, 10 eq.) and 10 mL acetyl chloride (0.108 mol, 3 eq.). The suspension is then placed in an ultrasonic bath for 3 hours. Then 200 mL of dichloromethane are added and the organic phase is washed with a saturated solution of sodium hydrogen carbonate. The organic phase is then washed with water up to pH=7, dried on sodium sulfate and evaporated to obtain 10.7 g of off-white solid of compound 19, used without further purification (R=92%).
1H-NMR (300 MHz, CDCl3) δ (ppm)=8.65 (s, 2H), 4.02 (s, 6H).
C2) Preparation of Compound 20
1.39 g sodium borohydride (36.6 mol, 1.1 eq.) are added to a solution of 10.7 g (33.3 mmol, 1 eq.) of compound 19 in 200 ml of a mixture of methanol/dichloromethane (140/60) and cooled to 0° C. The mixture is then stirred for 30 min at 0° C. and 30 min at room temperature. The reaction is then stopped by adding 50 mL of an hydrochloric acid solution (1M). The organic phase is then washed with water up to pH=7, dried on Na2SO4 and evaporated. The raw product is then purified on silica gel (eluent: dichloromethane with progressive addition of methanol (0 to 10%)) to obtain 5 g of a white powder of compound 20. (R=51%).
1H-NMR (300 MHz, CDCl3) δ (ppm)=8.39 (bd, 1H), 7.97 (bd, 1H), 4.82 (d, J=5 Hz, 2H), 3.99 (s, 3H) 3.04 (t, J=7 Hz, 1H).
C3) Preparation of Compound 21
To a solution of 1 g of compound 20 (3.4 mmol, 1 eq.) and 1.4 mL of triethylamine (10.2 mmol, 3 eq.) in 120 mL of dichloromethane are added 0.4 mL of mesyl chloride (5.1 mmol, 1.5 eq.). After 30 minutes of stirring (reaction followed by TLC), 100 mL of a saturated solution of NaHC03 is added. The organic phase is then washed with water, dried on Na2SO4 and evaporated. 1.1 g of yellow oil of compound 21 is obtained and used without further purification (R=95%).
1H-NMR (300 MHz, CDCl3) δ (ppm)=8.46 (s, 1H), 8.04 (s, 1H), 5.36 (s, 2H), 4.00 (s, 3H), 3.16 (s, 3H).
C4) Preparation of Compound 22
60 mg of triazacyclononane mono-boc 6 (0.2 mmol, 1 eq.) are suspended in 50 mL of dry acetonitrile under argon with 140 mg of anhydrous Na2CO3 (1.2 mmol, 6 eq.). A solution of 184 mg of compound 21 (0.5 mmol, 2.5 eq.) in dry acetonitrile is then added and the mixture is stirred for 12 hours at 60° C. under argon. After cooling, the mixture is filtered on sintered and evaporated. The residue is taken up by dichloromethane and purified on an alumina column (activity III; eluent: dichloromethane followed by ethyl acetate) to obtain 110 mg of pure compound 22 in the form of a white pasty solid (R=71%). 1H-NMR (300 MHz, CDCl3) δ (ppm)=8.34 (s, 2H), 8.22 (s, 1H), 8.11 (s, 1H), 3.97 (s, 6H), 3.94 (s, 4H), 3.4-2.58 (m, 12H), 1.47 (s, 9H).
13C-NMR (75 MHz, CDCl3) δ (ppm)=164.6, 162 (d, J=14 Hz), 155.61, 147.6 (d, J=14 Hz), 135.3 (d, J=14 Hz), 132.7, 106.6, 79.5, 63.1, 56.6, 54.9, 54.4, 53.1, 50.8, 50.2, 28.7. LC-MS: [M+H]+=780.0 m/z.
C5) Preparation of Compound 23
110 mg of compound 22 (0.14 mmol, 1 eq.) are dissolved in 50 mL of dichloromethane, then an excess of trifluoroacetic acid is added (3 mL). The mixture is then stirred at room temperature for 12 hours. The solvent is then evaporated and a mixture of 20 mL of dichloromethane and 10 mL of water is added. The aqueous phase is neutralized by adding a saturated solution of NaHCO3 and extracted with dichloromethane. All the organic phases are dried on sodium sulfate and evaporated. The result is 100 mg of white solid (quantitative yield) of compound 23, which is used without further purification.
71H-NMR (300 MHz, CDCl3) δ (ppm)=8.23 (s, 2H), 7.83 (s, 2H), 3.92 (s, 10H), 3.27 (s, 4H), 2.92 (s, 4H), 2.67 (s, 4H). 13C-NMR (75 MHz, CDCl3) δ (ppm)=164, 159.98, 147.81, 134.86, 133.14, 107.08, 59.85, 5336, 52.65, 49.87, 45.33. HR-MS: [M+H]+=680 m/z, theor. for C22I2H28N2O5 680.0225 m/z.
C6) Preparation of Compound 24
100 mg of compound 23 (0.15 mmol, 1 eq.) are suspended in 30 mL of water and 24 mg of sodium hydroxide (0.81 mmol, 4 eq.) are added. The mixture is then stirred at 60° C. for one hour. The complete hydrolysis of the ester functions is confirmed by LC-MS. The solution is then cooled, and its pH is adjusted to 5 with a progressive addition of a hydrochloric acid solution (1M). 5 mL of methanol are then added before introducing 42 mg of sodium carbonate to the solution. 66 mg of TbCl3, 6H2O (0.18 mmol, 1.2 eq) are added before stirring the mixture at 50° C. for 12 hours, after return to ambient temperature, the insoluble salts are filtered on sintered glass before evaporation of the solvents to obtain 200 mg of raw product. The complex is purified by steric exclusion chromatography (Sephadex® LH20, eluent: water) to obtain 36 mg of a colorless crystalline product (30% yield).
1H-NMR (300 MHz, D2O) δ (ppm)=122.8, 84.95, 82.17, 70.62, 49.22, 25.03, 20.8, −0.89, −8.54, −19.41, −33.05, −41.19, −67.6, −88.49, −90.57, −125.1.
HR-MS: [M+H]+=807.8921 m/z, theor. for C20H21I2N5O4Tb 807.8931 m/z.
D) Preparation of a Fourth Series of Triazacyclononane-Based Ligands (TACH)
D1) Preparation of Compound 25
1 g of compound 2 (6 mmol, 1 eq.) is dissolved in 100 mL methanol and 8 mL of a 30% aqueous ammonia solution (60 mmol, 10 eq.). This mixture is stirred at room temperature for 12 hours. The solvents are then evaporated to give 900 mg of a white solid of the pure compound 25 (=quantitative).
1H-NMR (300 MHz, C2D6SO) δ (ppm)=8.14 (bs, 1H), 7.96 (t, J=8 Hz, 1H), 7.88 (d, J=8 Hz, 1H), 7.61 (bd, J=8 Hz, 2H), 4.64 (s, 2H).
LC-MS: [M+H]+=153.2 m/z.
D2) Preparation of Compound 26
To 1 g of compound 25 (6.6 mmol, 1 eq.) in 20 mL DMF at 0° C., 4 mL thionyl chloride (53 mmol, 8 eq.) are added. The mixture is stirred for 2 hours, before being allowed to return to room temperature in 15 minutes. 150 mL water is then added before extracting the product with 30 mL dichloromethane. The organic phase is then washed with water to pH=7, washed in brine, dried on Na2SO4 and evaporated. The resulting residue is purified by silica gel chromatography (eluent: dichloromethane) and leads to the production of 720 mg of a white solid of compound 26 (R=55%).
1H-NMR (300 MHz, CDCl3) δ (ppm)=7.89 (t, J=8 Hz, 1H), 7.75 (d, J=8 Hz, 1H), 7.65 (d, J=8 Hz, 1H), 4.69 (s, 2H).
LC-MS: [M+H]+=153.3.
D3) Preparation of Compound 27
120 mg of triazacyclononane protected by a mono-Boc (0.4 mmol, 1 eq.) are dissolved in 50 mL of dry acetonitrile under argon with 252 mg of anhydrous anhydrous Na2CO3 (2.4 mmol, 6 eq.). A 151 mg solution of compound 26 (1 mmol, 2.5 eq.) in dry acetonitrile is then added and the mixture is stirred for 12 hours at 60° C. under argon. After cooling, the mixture is filtered on sintered and evaporated. The residue is taken up by dichloromethane and purified on an alumina column (activity III; eluent: dichloromethane followed by ethyl acetate) to give 160 mg of compound 27 in the form of a white pasty solid (R=83%).
1H-NMR (300 MHz, CDCl3) δ (ppm)=7.79 (dt, 3J=8 Hz, 4J=1 Hz, 2H), 7.70 (bd, J=8 Hz, 2H), 7.57 (dt, 3J=8 Hz, 4J=1 Hz, 2H), 3.91 (s, 4H), 3.36 (m, 4H), 3.03 (m, 4H), 2.66 (m, 4H), 1.47 (s, 9H).
LC-MS: [M+H]+=462.2 m/z.
D4) Preparation of Compound 28
225 mg of NaN3 (3.5 mmol, 10 eq.) and 185 mg of dry NH4Cl are added to a 160 mg solution of compound 27 (0.35 mmol, 1 eq.) in 40 mL of dry DMF under argon. The mixture is stirred at 120° C. for 12 hours. After cooling, sintered filtration and evaporation of the solvents, a residue is obtained, which is taken up by 50 mL hydrochloric acid (1M) and placed in an ultrasonic bath for 2 hours.HR-MS [M+H+]: 604.1439 th 604.1447
D5) Preparation of Compound 29
155 mg of compound 28 (0.35 mmol, 1 eq.) are suspended in 10 mL of water with 220 mg Na2CO3 (2.08 mmol, 6 eq.). After 10 min of stirring, 155 mg TbCl3*6H2O (0.42 mmol, 1.2 eq.) are added. The solution is then stirred for 12 hours at room temperature. After evaporation of solvents, the raw product is purified on a steric exclusion column. (Sephadex® LH20 in water) to finally obtain 40 mg of crystalline white solid (yield=20%).
HR-MS: [M+H]+=604.1439 m/z, theor. for C20H23N13Tb 604.1427 m/z.
E) Preparation of a First Series of Ligands Based on 1,7-dioxa-4,10-Diazacyclododecane
Compound 31 is prepared according to the method previously reported (M. Mato-Iglesias, Adrián Roca-Sabio, Z. Pálinkás, D. Esteban-Gómez, C. Platas-Iglesias, E. Tóth, A. de Blas, T. Rodríguez-Blas, Inorg. Chem., 2008, 47, 7840).
Part II: Crystallographic Studies
A) Model Proteins Studied
5 proteins, of which three commercial proteins were selected. The structure of these five proteins was known. These five proteins were chosen because of their physico-chemical differences. They belong to various organisms, have broad thermal properties and an oligomeric state ranging from monomer to hexamer. Tests with proteins of unknown structure were also carried out.
a. Commercial Proteins
The three commercial proteins selected are chicken's egg white lysozyme (HEWL), Thaumatococcus danielli Thaumatin and Tritirachium album Proteinase K. These three proteins are model proteins for crystallogenesis. They are purchased under freeze-dried form. They were solubilized in milliQ water just prior to crystallogenesis experiments at the desired concentration. These are presented in Table 1 below.
The conditions of native crystallization (i.e., without addition of complexes depending on the invention) of these proteins are known and described in Table 2 below. These conditions were used to characterize the effect of lanthanide complexes on the crystallogenesis of these commercial proteins.
a. Non-Commercial Proteins
The two non-commercial proteins (known structures) are Pyrococcus horikoshii Protease 1 and Pyrococcus furiosus reductase Glyoxylate hydroxypyruvate reductase. These two proteins have been purified according to the protocols described in the references below:
The technical details concerning these proteins are given in Table 3 below:
P. furiosus
P. horikoshii
The crystallization conditions for these two proteins are described in Table 4 below. These conditions allow the proteins to crystallize in their native form and are extracted from the same references as purification protocols.
The five proteins described above are the reference proteins for characterizing the effects of lanthanide complexes.
c. Unknown Proteins
The specificities of the three proteins with unknown structure are described in Table 5 below. The structure of the MDH-ANC80 protein was determined using the lanthanide 17 complex. The individual steps will be described individually in a separate section.
No crystallisation conditions were published for these two proteins. Sequence SEQ ID N° 1 to 7 are presented in ANNEXE1.
The ANC80 Malate Dehydrogenase (MDH) purification protocol is described in the literature (Madern et al. 1995 230 (3): 1088-95 Eur. J. Biochem).
The protocol for the purification of pb6 was established by Cécile Breyton's team from the M&P group of the Institut de Biologie Structurale and is as follows:
Pb6 Purification Protocol:
Expression system=E. coli BL21 (DE3) transformed with LIM1 (Kan R) His tag with cleavage site “Tobacco Etch Virus”.
Balancing buffer=20 mM Tris pH 8, 250 mM NaCl, 15 mM Imidazole
Elution buffer—20 mM Tris pH 8, 200 mM Imidazole
Flow rate=1 ml/min
Balancing buffer=20 mM Tris pH 8
Elution buffer=20 mM Tris pH 8 1M NaCl
Emission by linear gradient
Flow rate=1 ml/min
B) Automated Crystallization/Stability of Lanthanide Complexes
a. The HTXIab Platform.
To determine the crystallization conditions of a protein, the HTXIab platform was used to screen a wide range of crystallization conditions. These conditions are all described in the Tables in Appendix 2A and 2B and derived from https://embl.fr/htxlab/index.php?option=com_content&view=article&id=38&Itemid=172.
A conventional screening consists of 6 crystallization plates of 96 wells each, representing 576 conditions.
The studies conducted on MDH-ANC80 and Pb6 used the conditions described in Appendix 2A.
The studies carried out on the other proteins were carried out under the conditions described in Appendix 2B, due to a change due to the supplier.
Complex Stability
The stability studies were performed under the conditions described in Appendix 2A. Lanthanide complexes based on tris-dipicolinate (DPA) [Ln(DPA)3]3− have been shown to exhibit” self-crystallization “for certain crystallization conditions. In particular, the presence of divalent cations, high salt concentrations, the presence of MPD caused the self-crystallization of this type of complex (Doctoral thesis of R. Talon defended in Grenoble on Jun. 6, 2012). Two concentrations of Ln(DPA)33− have been evaluated (25 and 100 mM). Thus, out of 576 conditions, more than a quarter of the conditions lead to self-crystallization/precipitate formation of Ln(DPA)33− at 100 mM and of the order of 8% when used at 25 mM.
Equally, the stability of complex 10 was evaluated at 3 different concentrations (10, 50 and 100 mM). Complex 10, even at a concentration of 100 mM, exhibits increased stability. Indeed, no crystal of the complex was observed, as detailed below where only precipitates were detected.
Summary of the screening of the 6 classical plates for 100 mM of complex 10:
Plaque Hampton 3
Slight precipitation observed in the presence of NaHPO4 or KHPO4.
Plaque Hampton 5
Mostly PEGs in this case 100% of the drops are clear.
Plaque Hampton 4
Mostly salts. Some conditions are redundant with the Hampton 3 plate. Similar effect in the presence of HPO4− with slight observed precipitation.
Plaque Qiagen 1
Mixture of PEGs, salts and metals. A slight precipitate is observed in the presence of cadmium acetate.
Plaque Hampton 6
Slight precipitate observed in the presence of a mixture of metals (cadmium, zinc, cobalt).
Plaque Hampton 2
Slight precipitate in the presence of NaF and (NH4)2PO4
Below is a detailed description of the conditions that lead to these precipitates: With 100 mM of Complex 10 added to the standard conditions:
Hampton Plate 4: 21 precipitated conditions No. A7, B7, C7, C7, A8, B8, ABCD 9, 10, 11 and 12 (mainly ammonium phosphate)
Hampton Plate 5: No precipitate
Quiagen Plate 1: 6 precipitated conditions No. D6, B9, F9, F9, F9, D10, E10
Hampton 6 plate: 4 precipitated conditions No. A3, B3, C3, H8
Hampton Plate 2: 7 precipitated conditions No. C2, C5, B6, A7, C7, C7, A12, B12
Hampton Plate 3: 4 precipitated conditions No. H3, E4, A6, E5
This represents a total of 42 precipitated conditions. On a screening of 576 conditions this is equivalent to 7.3%;
No false positives like with DPA.
With 10 mM of complex 10 added to the standard conditions:
Hampton Plate 4: No precipitate marked as observed with some 100 mM, some trace of precipitate for ABCD line 12
Qiagen Plate 1: a slightly precipitated condition for E10
Wizard plate I and II rigaku 5 precipitated conditions No. E6, C7, B9, C10, H11
JCSG plate: 3 precipitated conditions No. D2 G5, A6
PACT Qiagen Plate: 5 precipitated conditions No. E1, A5, A6, E11, C12
PEGs Qiagen Plate: No precipitated condition
A total of 18 conditions with slight traces of precipitation. (3.2% of the screening) considering that drops with some traces of precipitate were described as “precipitated”. The amount and number of precipitating assays have nothing to do with the observed precipitates at 100 mM of complex 10, nor at 25 mM of (DPA)33−.
It should be noted that the presence of these precipitates is not incompatible with the appearance of protein crystals. In fact, manual crystallization tests of the C. aurantiacus MDH protein in the presence of cadmium have made it possible to obtain crystals in the presence of 50 mM of complex 10.
C) Screening of New Crystallization Conditions
To carry out a screening of six plates at the HTXIab platform, 100 μl of protein solution are required. In order to have a direct comparison, the native protein (without lanthanide complex) and the protein in the presence of 10 mM complex 10 were screened in parallel in the same crystallization plates.
a. Protocol for the Preparation of Protein Samples Containing Lanthanide Complex.
Lanthanide complexes were stored under powder form at 4° C. The mass corresponding to 10 mM per 100 μl of protein solution was weighed on a precision scale. The powder was centrifuged to form a pellet. This pellet was taken up by 100 μl of the protein solution. A two-minute centrifugation was carried out to eliminate any aggregates. The solution was then changed to a new tube. This protocol has been applied for all proteins sent to the robot.
b. Determination of New Conditions for Unknown Protein pb6
The most interesting conditions in terms of crystallogenesis and allowing the crystallization of pb6 are listed in Table 6. The conditions under which crystals were formed only in the presence of 10 mM of complex 10 are indicated in bold (they are pb6-I and pb6-4).
The pb6-I condition was reproduced manually in the laboratory and also gave crystals. The use of complexes according to the invention makes it possible to double the number of conditions that led to crystallization.
c. Determination of New Conditions for Unknown Protein MDH-ANC80
The most interesting conditions in terms of crystallogenesis and allowing the crystallization of protein ANC80 are listed in Table 7. The conditions which allowed the crystals to be generated only in the presence of 10 mM of complex 10 are mentioned in bold (they are ANC-1 and ANC-2).
The ANC-1 condition was replicated in the laboratory and allowed crystal growth (Paragraph D. a). The use of complexes according to the invention makes it possible to triple the number of conditions that led to a crystallization.
d. Statistics on the Crystals of the Different Proteins Studied on the HTXIab Platform
Table 8 below presents the number of conditions that led to crystals after conventional screening (576 commercial conditions for complex 10 and 480 for complex 31) at the HTXIab platform for the different proteins studied. The values indicated correspond to an observation of the crystallization plates after 85 days. The column “unique conditions” corresponds to the number of conditions that lead to crystallization in the presence of complexes, but no crystallization under the same conditions in the absence of complex (called natives).
Gallus
T. Album
P.
Horikoshii
P.
Horikoshii
P.
Furiosus
P.
Furiosus
T. Daniellii
Gallus
T. Album
The conditions leading to crystallization correspond to conditions leading to the appearance of crystals potentially exploitable for diffraction experiments. Complex 10 thus allows a significant increase in the number of crystallization conditions for the following proteins: HEWL and Pho protease I. While its effect may appear to be less effective in the case of Proteinase K and Thaumatin, that is not the case. Indeed, the introduction of Complex 10 does not lead to a significant increase in the number of lanthanide hits, but the conditions obtained are largely different from native conditions (21 for Proteinase K and 2 for Thaumatin). We increase then the number of potential conditions for obtaining crystals of the protein of interest,
It should be noted that in the case of the Protease I protein with complex 10, gaining 113 conditions is covering a wide range of different crystallization conditions. This proves once again that complex 10 is compatible with all the physico-chemical conditions that can be found in commercial crystallization kits.
Complex 10, like complexes 17 and 31, have all a nucleating effect. However, complexes 17 and 31 are less effective than complex 10. For example, complex 31 appears to be less effective than complex 10 for proteinase K. However, the 4 conditions leading to crystallization in the presence of complex 31 are different from those leading to native crystals. Those crystals are potentially of better quality. Obtaining new conditions leading to crystallization is therefore a step forward.
D) Hand-Held Laboratory Crystallizations
Commercial proteins (Paragraph A.a.) were manually crystallized according to known customary crystallization conditions (Table 2). The crystallization conditions described in Table 2 were therefore reproduced in the presence of 10 or 17 complexes at a concentration of 10 mM. To achieve these manual crystallization ranges, the crystallization drops were prepared according to the following scheme: 1.5 μl protein solution +1.5 μl complex solution at a concentration of 10 mM+1.5 μl precipitant solution. In order to highlight a potential effect of lanthanide complexes on crystallization, the precipitating agent range has been adjusted to be at the edge of the crystallization zone and eventually extended beyond when an effect was observed.
Thus, in the case of the lysozyme protein, a marked nucleating effect was observed. The nucleating effect should be understood here as the growth of crystals in the presence of the lanthanide complex at low concentrations of precipitating agents, concentrations which do not allow the formation of native crystals. In order to clearly highlight this nucleation phenomenon induced by complexes according to the invention, phase diagrams have been made by determining the ranges of concentration of precipitating agents and of protein that allow the crystals to be obtained.
a. Phase Diagrams for Native Chicken's Egg White Lysozvme and in the Presence of 10 mM Complex 10 or Complex 17
Phase diagrams of the lysozyme protein obtained after 2 days and 15 days of growth are shown in
Each crystallization condition was made in triplicate. After only two days of crystal growth, a clear difference was observed. In the presence of complex 10 or 17, crystals were obtained at both low concentrations of protein (5 mg/ml) and precipitating agent.
After 20 days of crystalline growth in the presence of complex 10 or 17 at 10 mM, crystals were obtained over the entire range evaluated. In particular, crystals have appeared for 5 mg/ml of lysozyme and for a precipitating concentration of 500 mM. By comparison, the absence of lanthanide complex only allows the formation of crystals up to 500 mM of NaCl and for concentrations of 20 mg/ml of protein.
For comparison purposes:
MRI complexes, which do not induce nucleating effects, are typically used at concentrations in the range of 50-300 mM.
b. Phase Diagram for Native Chicken's Egg White Lysozyme and in the Presence of 10 mM Complex 11 (Eu)
The phase diagram obtained in the presence of complex 11 (
c. Phase Diagrams for Protein of Unknown Structure pb6
The protein pb6 has been purified according to the protocol described above. The condition pb6-1 (Paragraph Cb) obtained at the HTXIab robot was reproduced manually. Phase diagrams were determined. They are shown in
Crystals obtained in the presence of 10 mM complex 10 are perfectly exploitable for diffraction experiments. Native crystals are too small, too thin and poorly organized. Thus, in the case of the protein pb6, a nucleating and crystallizing effect is observed induced by compound 10.
d. Crystallizing Effect of Lanthanide Complexes 10
If an improvement of crystallization (number of crystals, crystal size, diffraction improvement) is observed with the addition of lanthanide complexes, this is referred to a crystallization effect.
In the case of the crystallization of the Protease 1 protein of P. horikoshil, a crystallizing effect was also observed linked to the addition of complex 10. Indeed, the crystals obtained in the presence of 10 mM of complex 10 appeared on average 2.5 times larger than the crystals obtained under the same conditions, but without complex (average size evaluated on 10 crystals present in a photographed drop).
This crystallizing effect is therefore of great interest for X-ray crystallography since the diffraction intensity is proportional to the volume of the irradiated sample. This can thus provide a higher resolution for diffraction data.
E) Luminescence Properties and Applications.
The coordination complexes of terbium and europium (III) are known to have very particular luminescence properties, due to the f-f transitions that result in fine and characteristic emission lines of each element and long lifetimes (ps-ms). It is difficult to induce this luminescence by direct irradiation of the metal ion, because these f-f transitions are prohibited and therefore have very low molecular absorption coefficients. On the other hand, it is possible to sensitize this luminescence by an indirect process, called antenna effect, which consists in exciting an organic ligand containing a chromophore (typically an aromatic group) and transferring this energy to the metal ion (Luminescence of Lanthanide Ions in Coordination Compounds and Nanomaterials, Ed. A. De Bettencourt-Dias, Wiley 2014).
These luminescence properties of the proposed lanthanide complexes can be used in two steps in determining the structure of a protein: a) crystal detection during crystallization and b) crystal centering during the diffraction experiment.
a. Crystal Detection During Crystallization
Detection of crystals can sometimes be complicated, for example when the crystals are small, drowned into a precipitate or obtained at the edge of a crystallization drop. In the particular case of membrane proteins, we can also mention the problem of detecting crystals obtained by the crystallization technique of lipidic cubic phase.
To improve the crystals detection, many suppliers offer microscopes with a UV source, allowing the intrinsic fluorescence of aromatic amino acids, especially tryptophan. Examples include the UV source proposed by Molecular Dimension (http://www.moleculardimensions.com/applications/upload/Xtalight“100.pdf) or the UVEX microscope (http://www.moleculardimensions.com/shopdisplayproducts.asp? id=299&cat=UVEX+UV+Fluorescence+Imaging+systems) offered by the same company.
The use of lanthanide complexes luminescence can help to solve many of the problems mentioned above.
The luminescence of lanthanide complexes according to the invention has therefore been studied, using a UV source currently being marketed by NatXray on a conventional microscope and an external OceanOptics LED UV source (
Using the NatX-ray system, the crystals obtained in the absence of Complex 10 appear blue (on the left). Conversely, those obtained with this complex appear green (on the right) which results in a contrast increase between the crystals and the surrounding solution. This can also be observed with the system using a UV LED source, since the crystals obtained in the presence of Complex 17 and under UV illumination are easier to identify than when observed in white light. For example, a small crystal is indicated by a white arrow (
It should also be noted that luminescence is observable at two excitation wavelengths (280 nm and 365 nm).
b. Crystal Centering Aid
This part was evaluated using the IBS-ESRF CRYOBENCH instrument (http://www.isbg.fr/analyses-structurales/cryobench/) and the ESRF FIP-BM30A light line.
The crystals used (lysozyme crystals obtained in the presence of 10 mM of complex 10 or crystals of the protein MDH ANC80 obtained in the presence of 50 mM of complex 17) were conventionally frozen at 100 K on nylon loops.
To take pictures, the same external UV LED light source from OceanOptics was used. The quality of the photos obtained makes it possible to consider different ways for facilitating centering:
F) Phasing Potential of Lanthanide Complexes According to the Invention
a. Methodology Used
The evaluation of the phasing potential of lanthanide complexes according to the invention was carried out in a conventional manner, using different de novo phase-determining methods, representing a panel of commonly used techniques for the determination of biological macromolecular structures. This shows that the use of complexes according to the invention allows a habitual use of phasing methods.
The tested methods are:
Diffraction data were integrated and scaled with the XDS, SCALA and TRUNCATE programs.
The AutoSharp program (https://www.globalphasing.com/sharp/) has been used. This program automatically searches for the position of heavy atoms, refines them, determines the initial phases and improves them. The program was used with the default settings. The result of the phasing is evaluated on the basis of the merit figures (FOM for “Figure of Merit”), before and after phase improvement.
In a second step, the quality of the phasing was evaluated by automatically reconstructing the model of the protein under consideration. The number of residues modelled is then available compared to the expected number of residues. The Buccaneer program (http://www.ccp4.ac.uk/dist/html/cbuccaneer.html) was used with the default settings and with 10 rebuild cycles.
The diffraction data are conventionally recorded on a synchrotron light line. In order to determine the precise absorption threshold of lanthanide LIII of the lanthanide used, a fluorescence measurement was performed and processed using the Chooch program (http://www.gwyndafevans.co.uk/chooch.html). The recording wavelengths are thus obtained, in order to optimize the use of the lanthanide anomalous signal (SAD and MAD methods). In the case of the SIRAS method and in addition to recording at the LIII threshold of the lanthanide on the derivative crystal, a native crystal recording was made at the wavelength of 0.9798 Å. The results are shown in
For each of the phasing methods evaluated, the recordings were made at the wavelengths indicated in Table 9:
b. Crystallized Protein Diffraction Test in the Presence of 10 mM of Complex 10 or 17
Crystals of co-crystallized proteins in the presence of 10 mM of complex 10 or 17 (nucleating effect conditions of the lanthanide complex) were evaluated in terms of diffraction. The results of this assessment are summarized in Table 10:
In the case of Protease 1 protein, the crystallizing effect manifests itself both by an increase in the average crystal size, as indicated above, and by the resolution obtained for diffraction. The diffraction data recorded on a crystal obtained in the presence of 10 mM of complex 10 has a resolution of 1.7 Å. The best model currently available in the Protein Data Bank is at 2.0 Å (PDB code: 1G2I Publication reference: idem protocol part 1b).
c. De Novo Phasing of Model Proteins
The structures of the different model proteins were determined according to the different methods explained in paragraph F.a.
In addition, phasing attempts were carried out on crystals obtained under nucleating conditions of the complex (i.e. at 10 mM), but the possibility of soaking a crystal obtained in the presence of 10 mM of complex 10 or 17 in a solution similar to the crystallization condition and containing 100 mM of the lanthanide complex was also studied. This was intended to eventually increase the protein's tagging rate and thus facilitating the determination of its structure. The soaking time was about one minute. It should be noted that this soaking technique can also be applied to native crystals (obtained in the absence of lanthanide complex).
To summarize, the following three crystal preparation methods were evaluated for a de novo phasing using lanthanide complexes according to the invention:
The diffraction data set was obtained in accordance with the methodology explained in paragraph F. a. The results are presented in Table 11 below.
The high phasing power of the complex objects of the present invention is reflected in the percentage of model reconstructed without manual intervention. The more the quality of the phase determination (depending on the phasing method used, the occupancy of the complex fixing sites, the data quality, etc.), the more the experimental electronic density map can be interpreted by automatic reconstruction programs (such as the Buccaneer program). In the evaluated cases, models automatically rebuilt from 50% to almost 100% of the final model have been obtained.
d. Examples of Electronic Density Obtained After Phasing and Solvent Flattening
An example of experimental electron density obtained using the methods described above for glyoxylate reductase protein and Protease 1 protein are shown in
In both cases, given the quality of phase determination, easily interpretable experimental electronic density maps are obtained, where one can distinguish side chains of amino acids. A tyrosine for the glyoxylate reductase map and a tryptophan for the Protease 1 Protein map. The images were produced using the coot software.
G) Application of the Technology to the Determination of the Structure of the MDH ANC80 Protein
a. Nucleating and Crystallizing Effect: the Case of MDH ANC80
The MDH ANC80 protein concentrated at 10 mg/ml was sent to the crystallization robot for a conventional screening of the 576 conditions. The most promising crystallization condition is the condition ANC-1 in Table 7. The photos obtained in the crystallization robot for this condition are shown in
This condition was reproduced manually in the laboratory. Crystals appeared in the presence of 10 mM of complex 17 and 10 mM of complex 10 in 7 days. The same condition in native condition (without lanthanide complex) was also performed. After about 3 weeks, crystals of different shapes appeared (not shown).
The native crystals have been tested for diffraction. The resolution is in the order of 2.5 Å. Those crystals have a different symmetry from that obtained for crystals obtained in the presence of complex 10 or 17 (Space group F222) with mesh parameters of 81,140 and 395 Å respectively for a, b, and c. This is compared to the space group obtained for crystals in the presence of complex and the resolution obtained for diffraction data. The crystals in the presence of 10 mM of lanthanide complex diffract at 1.7 Angstrom. Thus, the nucleating and crystallizing effects are properly observed in the case of this protein.
The structure of the ANC80 MDH was determined using the MAD method. Three datasets were recorded on the same crystal at the terbium absorption threshold LIII. An additional dataset was measured at the selenium absorption threshold K to obtain the best possible resolution. The statistics, after integration across all the data collected, are presented in Table 12 below.
The refinement of the model leads to very good quality factors with a R and Rfree factor of 19.2% and 21.2%.
The following luminescent complexes have also been tested at 10 mM and do not have any effect on crystallization:
| Number | Date | Country | Kind |
|---|---|---|---|
| 15 62880 | Dec 2015 | FR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/FR2016/053539 | 12/16/2016 | WO | 00 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2017/103545 | 6/22/2017 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 20100247448 | Gateau | Sep 2010 | A1 |
| Number | Date | Country |
|---|---|---|
| 2 991 322 | Dec 2013 | FR |
| 02088435 | Nov 2002 | WO |
| 2014162105 | Oct 2014 | WO |
| Entry |
|---|
| James W. Walton et al., Isostructural Series of Nine-Coordinate Chiral Lanthanide Complexes Based on Triazacyclononane, Inorg. Chem, 51(15), 8042-8056. (Year: 2012). |
| Corneillie et al., “Crystal Structures . . . Chiral System”, Journal of the American Chemical Society, American Chemical Society, 2003, vol. 125, No. 49, pp. 15039-15048. |
| E. Girard et al., “A new class . . . macromolecular crystallography”, Acta Crystallographica Section D, 2003, pp. 1914-1922. |
| Pompidor et al., “Protein Crystallography . . . and Arginine”, Angewandte Chemie International Edition, 2008, vol. 47, No. 18, pp. 3388-3391. |
| Mato-Iglesias et al., “Lanthanide Complexes . . . Contrast Agents”, Inorganic Chemistry, American Chemical Society, 2008, vol. 47, pp. 7840-7851. |
| Palinkas et al., “Stability, Water . . . the Gd Complex”, Inorganic Chemistry, American Chemical Society, 2009, vol. 48, pp. 8878-8889. |
| Inmaculada et al., “Crystallization of . . . lanthanide complexes”, Act Crystallographica, 2010, vol. 64, No. 4, pp. 448-451. |
| Roca-Sabio et al., “The effect of . . . picolinate pendants”, Dalton Transactions, Royal Society of Chemistry, 2011, vol. 40, pp. 384-392. |
| Rodriguez-Rodriguez et al., “Lanthanide (III) Complexes . . . Hydration Number”, Inorganic Chemistry, 2012, vol. 51, No. 4, pp. 2509-2521. |
| Talon et al., “Clicked europium . . . structure determination”, Chemical Communications, 2012, vol. 48, No. 997, pp. 3388-3391. |
| Bijelic et al, “Hen Egg-White . . . Centred Polyoxotungstate”, ChemBioChem, 2015, vol. 16, pp. 233-241. |
| Regueiro-Figueroa et al., “Stabilizing Divalent . . . Electrostatic Effects”, Inorg. Chem., 2015, vol. 54, pp. 4940-4952. |
| K. Allen et al., “Lanthanide-tagged-proteins—an illumination partnership”, Current Opinion in Chemical Biology, vol. 14, 2010, pp. 247-254. |
| D'Arcy et al., “using natural seeding . . . protein crystallization experiments”, Biological Crystallography , vol. 59, pp. 1343-1346, 2003. |
| Dauter et al., “Novel approach . . . with halides” Biological Crystallography, pp. 232-237, 2000. |
| Dumont et al., “Exploration of the . . . and NMR study” Phys. Chem. Chem. Phys. 2013, vol. 15, pp. 18235-18242. |
| G. Falini et al., “Protein crystallization . . . mica surfaces”, Acta Crystallogr D. Biol. Crystallogr. vol. 58, pp. 1649-1652, 2002. |
| E. Girard et al., “A new class of . . . from Aspergillus Flavus”, Acta Crystallographica, 2003, D59, 118-126. |
| E. Girard et al., “High-phasing-power lanthanide . . . using synchrotron radiation” Acta Crystallographica, 2003, D59, 1877-1880. |
| S. Khurshid et al., “Automating the application . . . for protein crystallization”, Acta Cryst. D, vol. 71, pp. 534-540, 2015. |
| R. Matar-Merhab et al., “Structuring Detergents . . . Membrane Proteins”, PloS ONE, Mar. 2011, vol. 6. |
| A. McPherson et al., “Heterogeneous and . . . Mineral Surfaces” Science, vol. 239, pp. 385-387, 1988. |
| R. Nagem et al., “Protein crystal . . . anomalous scatterers”, Acta Crystallographica D, D57, pp. 996-1002, 2001. |
| E. Pechkova et al., “Protein Nucleation . . . Film Template”, Journal of Cellular Biochemistry 85:243-251 (2002). |
| M. Purdy et al., “Thiol-ractive lanthanide . . . diffraction data”, Acta Crystallographica D58, pp. 1111-1117, 2002. |
| E. Saridakis et al., “Protein crystallization . . . imprinted polymers”, Proceedings of the National Academy of Sciences, vol. 108, pp. 11081-11086, 2011. |
| N. Silvaggi et al., “Double-Lanthanide-Binding Tags . . . Structure Determination”, J. Am. Chem. Soc., vol. 129, pp. 7114-7120, 2007. |
| X. Su et al., “[Ln(DPA)3]3- Is a Convenient . . . NMR Studies”, J. Am. Chem. Soc., vol. 131, pp. 10352-10353, 2009. |
| M. Sugahara et al., “Nucleant-mediated protein . . . synthetic zeolites”, Acta Crystallographica D Biol. Crystallography, vol. 64, pp. 686-695, 2008. |
| Number | Date | Country | |
|---|---|---|---|
| 20180362550 A1 | Dec 2018 | US |
